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Abstract
Pseudomonas aeruginosa is one of the most virulent and resistant non-fermenting Gram-negative pathogens in the clinic.
Unfortunately, P. aeruginosa has acquired genes encoding metallo-b-lactamases (MbLs), enzymes able to hydrolyze most b-
lactam antibiotics. SPM-1 is an MbL produced only by P. aeruginosa, while other MbLs are found in different bacteria.
Despite similar active sites, the resistance profile of MbLs towards b-lactams changes from one enzyme to the other. SPM-1
is unique among pathogen-associated MbLs in that it contains ‘‘atypical’’ second sphere residues (S84, G121). Codon
randomization on these positions and further selection of resistance-conferring mutants was performed. MICs, periplasmic
enzymatic activity, Zn(II) requirements, and protein stability was assessed. Our results indicated that identity of second
sphere residues modulates the substrate preferences and the resistance profile of SPM-1 expressed in P. aeruginosa. The
second sphere residues found in wild type SPM-1 give rise to a substrate selectivity that is observed only in the periplasmic
environment. These residues also allow SPM-1 to confer resistance in P. aeruginosa under Zn(II)-limiting conditions, such as
those expected under infection. By optimizing the catalytic efficiency towards b-lactam antibiotics, the enzyme stability and
the Zn(II) binding features, molecular evolution meets the specific needs of a pathogenic bacterial host by means of
substitutions outside the active site.
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Introduction
b-lactam antibiotics (penicillins, cephalosporins, monobactams
and carbapenems) are the most dependable and frequently employed
chemotherapeutic agents for eradicating bacterial infections [1].
Their safety and efficacy as antimicrobial agents derives from their
ability to selectively inhibit cell wall biosynthesis, provoking bacterial
cell wall lysis [2]. The newest types of b-lactam antibiotics (e.g.
carbapenems) and expanded-spectrum cephalosporins (e.g. cefe-
pime), evade most common mechanisms of resistance against these
compounds [3]. These compounds are currently used as ‘‘last resort’’
drugs for treating multi-resistant gram-negative pathogens [1,3].
The major mechanism of resistance against b-lactam antibiotics
is the production of bacterial b-lactamases which catalyze cleavage
of the antibiotic b-lactam ring rendering an inactive derivative [2].
b-lactamases fall into four classes (A–D). Classes A, C and D are
serine-b-lactamases (SbLs) which employ an active-site serine to
catalyze antibiotic hydrolysis, while metallo-b-lactamases (MbLs),
or class B b-lactamases, are metallo-enzymes requiring one or two
zinc ions for their activity [4].
MbLs gained importance in the 1990s as the principal me-
chanism of resistance against carbapenems (imipenem, meropenem)
[5,6,7]. MbLs degrade all classes of b-lactams except monobactams
and, unlike most SbLs, these enzymes are not susceptible to
therapeutic b-lactamase inhibitors. This fact, together with the facile
dissemination of MbL genes among different clinical pathogens,
relegates them as a serious clinical threat [5,7]. Indeed, outbreaks of
pathogens producing NDM-1, IMPs, VIMs or SPM-1 MbLs are
increasingly common worldwide [8].
Atomic structures reveal that clinically relevant MbLs (subclass
B1) possess similar active sites: indeed, residues binding the essential
Zn(II) ions (first sphere residues) are strictly conserved (Figure 1A)
[6,7]. Despite being ‘‘broad-spectrum’’ enzymes, MbLs exhibit
quite different substrate profiles, which cannot be correlated to
different active site structures [9]. Many structural and mechanistic
studies have focused on the analysis of active site residues and the
role of active-site flanking loops to account for substrate recognition
of MbLs [6,9,10]. However, the mechanism by which different B1
enzymes are tailored to hydrolyze some antibiotics better than
others is not known. The fundamental question remains: how does
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protein evolution occur among MbLs that are found exclusively and adapted to a
particular host? This problem represents a central issue in linking
molecular features to organismal behavior. In the clinic this notion
may contribute to therapeutic failure.
Pseudomonas aeruginosa is one of the most clinically important non-
fermenting Gram-negative pathogens, being well known for its
ability to acquire genes encoding resistance determinants, such as
the acquired MbLs [11,12]. In addition, P. aeruginosa harbors a
host of virulence factors. Of particular relevance, SPM-1 is an
MbL produced only by P. aeruginosa, while other MbLs have been
found in many different bacterial hosts [12,13,14,15,16,17,18]. At
the present time, the blaSPM-1 gene is associated with a single clone
(SP/ST 277) of P. aeruginosa. This clone emerged relatively recently
in South America. This unique dissemination suggests either: 1)
the blaSPM gene came from another organism and has expanded in
SP/ST 277 because of a fitness advantage; or that 2) this genetic
determinant may have been optimized to meet the need of its
native host. SPM-1 in P. aeruginosa is therefore a unique system to
analyze the role of host-specific constraints in molecular evolution.
The structure of SPM-1 has revealed unique features among
pathogen-associated MbLs [19]. Spencer and coworkers have
shown that clinically relevant B1 enzymes share a hydrogen
bonding network spanning below the active site base, generally
known as second sphere residues (Figure 1) [19]. This network is
disrupted in SPM-1 due to the presence of two atypical second
sphere residues: S84 and G121, which replace the conserved D84/
R121 couple (Figure 1B) [9].
Here we examine the role of these positions (located outside the
enzyme active site ‘‘in the second sphere’’) and their impact on
antibiotic resistance in the native bacterial host, P. aeruginosa. We
report that this unique combination of residues is able to provide
resistance to anti-pseudomonal b-lactams such as latest generation
cephalosporins and carbapenems [11], while sacrificing the
catalytic efficiency against other b-lactams. Our findings reveal
that second sphere residues are able to modulate the substrate
specificity of MbLs according to the requirements of the bacterial
host In addition, we show that these second sphere residues
optimize the zinc binding affinity of SPM-1 in the bacterial
periplasm, providing P. aeruginosa antibiotic resistance under zinc-
limiting conditions, such as those prevalent during bacterial
infection [20,21].
Results
Mimicking the natural host of SPM-1
E.coli is usually employed as a model bacterial host to compare
the ability of the different MbLs to confer resistance, even for
enzymes which are not found in Enterobacteriaceae [9]. We
designed a system aimed to reproduce the native conditions of
expression of the blaSPM-1 gene. The complete blaSPM-1 transcrip-
tional unit from the clinical strain P. aeruginosa 48-1997A [15] (i.e.,
including the natural promoter, the leader peptide for periplasmic
location, the mature protein and the transcriptional terminator)
was amplified and subcloned into the broad-spectrum vector
pBBR1-MCS5 [22], replicative in P. aeruginosa PAO (Figure 2A). P.
aeruginosa PAO cells transformed with this vector (pDEP-SPM-1)
were able to express SPM-1, export and process it properly to the
periplasmic space. Western blot analysis showed two SPM-1 forms
of 30.6 and 27.5 kDa in whole cell extracts, corresponding to
the precursor and mature species respectively [13]. Instead, the
periplasmic fraction contained only the mature form of the
enzyme (Figure 2B,C). Accordingly, the transformed cells were
resistant to imipenem.
Codon randomization and selection of resistance-
conferring mutants
In order to assess the ‘‘flexibility’’ of positions 84 and 121 in
accommodating residues different from the native ones (S84 and
G121), codons 84 and 121 were individually randomized in blaSPM-1
by overlap-extension PCR [23,24]. The amplifications were
targeted to the mature blaSPM-1 coding sequence, and then subc-
loned into the screening vector, so as to avoid undesired mutations
in promoter and terminator sequences. In addition, codons 84 and
121 were randomized together looking for possible synergistic
effects between these positions.
Single-codon random libraries gave rise to 103–104 transfor-
mants, while the double-codon mutant library elicited .36104
transformants. According to Poisson distribution, the libraries
obtained have a probability of harboring a mutant blaSPM-1 gene
with a specific codon at position 84 or 121 (or a specific com-
bination of codons) .99% [23]. Sequences of ten randomly
selected mutants from each library indicated no obvious bias.
Active mutants were selected by examining the ability of the
different libraries to confer resistance toward different types of b-
lactam antibiotics in P. aeruginosa PAO (Figure 3). Paper discs
embedded with different antibiotics were applied onto LB-Gm
agar plates with P. aeruginosa PAO transformed with the ran-
domized libraries. We employed a penicillin (piperacillin), a third-
generation cephalosporin (ceftazidime), a cephamycin (cefoxitin),
and a carbapenem (imipenem).
Twenty bacterial clones exhibiting resistance (i.e., located within
the halos) were isolated for each library and for each tested
antibiotic (a total of 240 clones). Plasmids were extracted and
blaSPM-1 was sequenced in each clone. In total, 16 different
variants (wild type SPM-1, 10 single mutants and 5 double
mutants) were isolated. As expected, wild type clones (with residues
S84 and G121) were selected in all cases. Mutants G121A, S84N
and S84N/G121S were also selected against all tested antibiotics
(Figure 3). On the other hand, some substitutions were isolated
depending on the screening antibiotic, implying that positions 84
and 121 modulate the substrate profile of the enzyme. Surpris-
ingly, none of the selected mutants carried mutations G121R or
G121H (prevalent in B1 and B3 enzymes, respectively). Substitu-
tions at position 84, instead, displayed typical residues from B1
(S84D), B2 (S84G) and B3 enzymes (S84N), among others [9].
The S84D/G121S combination is present in the B1 enzyme
Author Summary
The presence of Zn(II)-containing metallo-b-lactamases
(MbLs) that confer resistance to all penicillins, cephalospo-
rins and carbapenems in Pseudomonas aeruginosa adds
significantly to the threat of this pathogen in our health
care system. SPM-1 is an MbLs widely distributed in South
America and only found in P. aeruginosa. In common with
all MbLs, the active site residues are highly conserved. In
this work we asked the following question: how would
substrate specificity evolve in SPM-1 if the active site
residues are highly uniform and do not permit substitu-
tions. To this end, we explored the role of two amino acids
(S84 and G121) that are outside the active site (second
sphere) and are unique in the SPM-1 b-lactamase. We
discovered that replacing these amino acids impacts
resistance to cephalosporins and carbapenems and that
this resistance profile depends on the enzymatic behavior
and the availability of Zn(II) in the environment. This work
demonstrates how protein evolution by means of subtle
substitutions outside the active site meets the specific
needs of a pathogenic bacterial host.
Host-Specific Enzyme-Substrate Interactions
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IMP-1, closely related to SPM-1 [13]. We then analyzed the
resistance profile of the libraries.
Second sphere mutations affect substrate-dependent
resistance in P. aeruginosa
MIC values for P. aeruginosa cells expressing each of the selected
SPM-1 mutants were determined against different antibiotics.
Cefepime (an antipseudomonal cephalosporin) was added to the
initial set of antibiotics. Expression of SPM-1 markedly increased
resistance towards antipseudomonas drugs such as ceftazidime and
cefepime (200–250 times), while for cefoxitin (an antibiotic to
which P. aeruginosa PAO is naturally resistant), the increase in MIC
was only 7-fold (Figure 4).
In general, single-codon variants S84G, S84N (naturally present
in B2 and B3 enzymes) and G121A (the most conservative
substitution in this position) display the highest MIC values after
the wild type (WT) enzyme (MIC values equal or up to 2-dilutions
lower compared to WT SPM-1). In fact, together with S84N/
G121S, these mutants were the most ubiquitous in the antibiotic
selection experiments. Synergistic effects between residues 84 and
121 are apparent when comparing double mutants vs. single
mutants. For example, while S84G and G121S mutations were
detrimental for resistance against piperacillin (MIC values appro-
ximately half a dilution lower than for WT), the combination of
both mutations generated an enzyme conferring higher levels of
resistance than the wild type (MIC value of 16 mg/ml for S84G/
G121S vs. 10 mg/ml for WT SPM-1) (Figure 4). Surprisingly, the
S84D/G121S combination, naturally occurring in IMP enzymes,
was not among the most resistant mutants for any of the antibiotics
assayed (MIC values 2–3 dilutions lower compared to WT SPM-1).
Figure 4 summarizes our data showing that mutations had
different impact in the bacterial resistance profile depending on
the antibiotic (selection criteria). Therefore, second sphere
positions 84 and 121 are able to shape the resistance profile,
and possibly the substrate specificity. In general, mutants
conferred lower levels of resistance than wild type SPM-1 (within
a range of 5 dilutions in MIC values). Surprisingly, piperacillin is
an exception, since four mutants outperform the wild type variant
(S84N, S84N/G121S, S84Q/G121S and S84G/G121S in up to
half a dilution in MIC values). In the case of cefoxitin, the range of
MIC values spanned by the different variants is smaller than for
Figure 1. (A) Location of first shell (green) and second shell (orange) residues in the structure of SPM-1. (B) Schematic representation
of the active sites of the B1 MbLs NDM-1 and SPM-1 emphasizing the differences in the hydrogen bond networks involving metal ligands (H116,
H118, H196, D120, C221 and H263, in green) and second sphere residues (115, 84, 121, 69, 70 and 262, in orange) due to residues 84 (D or S) and 121
(K or G).
doi:10.1371/journal.ppat.1003817.g001
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the rest of the tested antibiotics (3 dilutions vs. 4 or 5 dilutions).
The impact of mutations on MIC values is more informative for
the case of the antipseudomonas compounds ceftazidime and
cefepime, where several single and double mutants provide levels
of resistance comparable to the WT enzyme, with MIC values
increasing by two orders of magnitude. For imipenem, G121A is
the only mutant giving rise to a large MIC value (35 mg/ml vs.
48 mg/ml for WT SPM-1).
Figure 2. (A) Plasmid pDEP-SPM-1, showing the transcriptional unit (UT blaSPM-1 in red) harboring gene blaSPM-1. (B) Imipenem
antibiograms of P. aeruginosa PAO containing plasmids pBBR-MCS5 and pDEP-SPM-1. (C) Immune detection of SPM-1 in a crude extract and
periplasmic fraction of P. aeruginosa PAO pDEP-SPM-1.
doi:10.1371/journal.ppat.1003817.g002
Figure 3. Residues present at positions 84 and 121 in selected mutants for each antibiotic selection and library in P. aeruginosa PAO.
IMI = imipenem, PCL= piperacillin, CAZ= ceftazidime, CXT = cefoxitin.
doi:10.1371/journal.ppat.1003817.g003
Host-Specific Enzyme-Substrate Interactions
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Figure 4. Minimum inhibitory concentration (MIC) of imipenem (IMI), piperacillin (PCL), ceftazidime (CAZ), cefoxitin (CXT) and
cefepime (CFP) for selected strains of P. aeruginosa (producing the different SPM-1 mutants at positions 84 and 121). No SPM-1= P.
aeruginosa containing the vector pBBR-MCS5. Values come from 5 independent determinations.
doi:10.1371/journal.ppat.1003817.g004
Host-Specific Enzyme-Substrate Interactions
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Enzymatic activity in periplasma parallels the resistance
profile and reveals that SPM-1 is tailored to improve
resistance against drugs with anti-pseudomonal activity
Enzymatic studies in vitro of MbLs have been useful to uncover
structural and mechanistic aspects of these enzymes. However,
these data rarely correlate with the in vivo behavior [9]. We
attempted to correlate the MIC values with the hydrolytic profile
of the different SPM-1 mutants assayed in periplasmic extracts of
P. aeruginosa, i.e., in an environment closer to in vivo conditions. The
b-lactamase activity of SPM-1 mutants was assayed in periplasmic
extracts of P. aeruginosa PAO (in periplasma) and normalized relative
to the amount of enzyme present in the periplasm (quantitated
from Western blot gels). Given that SPM-1 is an efficient
cephalosporinase in vitro, we focused on these substrates. We
employed three substrates with antipseudomonal activity already
used in the MIC experiments: ceftazidime, cefepime and the
carbapenem drug imipenem, together with two first-generation
cephalosporins devoid of antipseudomonal activity (cephalexin
and cephalothin).
Hydrolysis rates in periplasma show a very good correlation with
MIC values in the case of cefepime and imipenem (Figure 5). For
these two substrates, only mutant G121A was competitive with the
performance of wild type SPM-1. Instead, in the case of cefta-
zidime, cephalotin and cephalexin, the hydrolytic performance of
the wild type enzyme was surpassed by several mutants. Mutant
S84G (present in B2 enzymes), and to a lesser extent S84N
(present in B3 enzymes) were the variants eliciting the best
performance for first-generation cephalosporins. We conclude that
the second coordination sphere modulates the substrate specificity
in SPM-1 so that this enzyme is adapted to better hydrolyze the
latest antipseudomonal antibiotics (cefepime and imipenem) while
the catalytic performance against first-generation drugs is far from
being optimized. In all cases, the activity of endogenous AmpC
was negligible (as revealed by the lack of activity in the ‘‘No SPM-
1’’ control strains).
Ceftazidime shows a different profile: albeit being an antipseu-
domonal drug, can be better hydrolyzed by several mutants than
by native SPM-1. However, P. aeruginosa has developed different
resistance mechanisms against ceftazidime which do not affect
cefepime and imipenem (hyperproduction of endogenous AmpC,
deregulation of efflux pumps or acquisition of ESBLs) [11]. We
therefore evaluated the role of SPM-1 in the resistance of the P.
aeruginosa clinical strain against these three antibiotics. Disks em-
bedded with ceftazidime, cefepime and imipenem were paired
with disks containing dipicolinic acid (DPA, an inhibitor of SPM-
1), on an agar plate inoculated with the clinical strain P. aeruginosa
48-1997A (including its native blaSPM-1 gene) and the control P.
aeruginosa PAO expressing SPM-1 [25]. While halos of inhibition
were similar for all antibiotics in the control strain, ceftazidime
exhibited a reduced halo in the clinical strain (Figure 6). When
DPA was added to whole cell extracts of the model strain, no
residual activity was monitored. Instead, residual ceftazidime
hydrolysis was present after addition of DPA to extracts from the
clinical strain (Figure 6). We conclude that resistance against
ceftazidime in the clinical strain is not exclusively due to
expression of SPM-1, and therefore this drug has not elicited a
significant evolutionary pressure on this enzyme (or a higher
activity against this antibiotic was not necessary a part of the
substrate spectrum in order to be acquired by P. aeruginosa). In fact,
there is evidence of SPM-1 producing isolates of P. aeruginosa that
express AmpC (probably due to an hyperproduction phenotype)
and OXA-52 enzymes, supporting our hypothesis [26].
We postulate that SPM-1 in the bacterial host has been exposed
to the evolutionary pressure of the administration of newest
antibiotics such as cefepime and imipenem, thus adapting to better
hydrolyze these compounds by changes in the second coordination
sphere. At this point, it is intriguing that mutant G121A, providing
high levels of resistance and hydrolysis rates in the periplasm, has
not been selected during natural evolution.
Limiting Zn(II) conditions have exerted evolutionary
pressure in selecting SPM-1 as the optimal variant in P.
aeruginosa
MbLs are exported to the bacterial periplasm as unfolded
polypeptides [27]. Therefore, in the apo (non-metallated) form,
metal site assembly (giving rise to the active variants) takes place in
the periplasmic space [27]. We have recently shown that Zn(II)
availability is limited in this compartment, and that MbLs with
reduced Zn(II) binding capabilities are unable to confer resistance
[28]. We determined the MIC values of P. aeruginosa cells with
different SPM-1 mutants in media containing excess or limiting
concentrations of Zn(II) against cefepime. MIC values were
unaffected by Zn(II) supplementation in all cases. However, under
metal deprivation conditions (by adding the chelating agent DPA),
strikingly distinct effects were observed for the different SPM-1
variants (figure 7).
Mutant G121A, exhibiting a high specific activity in periplasma
(Figure 5), was the most sensitive variant to metal deprivation
(MIC values are 64-fold lower in 1 mM DPA) followed by variants
S84K and G121D. Wild type and mutant G121S, on the other
extreme, were almost unaffected by these conditions (MICs values
diminished in only one-dilution in 1 mM DPA). The bacterial
growth was also unaffected by these conditions as assayed by MIC
values for the strain without the SPM-1 expression system. The
lack of effect of excess Zn(II) in bacterial resistance likely reflects
the action of the CzcABC pump in P. aeruginosa which, by
extrusion of excess Zn(II) into the extracellular medium, keeps
constant the levels of periplasmic Zn(II).
Thus, the second coordination sphere exquisitely tunes the zinc
binding ability of SPM-1 so that the enzyme has been evolved to
provide resistance at metal limiting concentrations. As a result, the
atypical S84/G121 combination allows SPM-1 to confer antibiotic
resistance under these conditions.
Protein stability determines the Zn(II) binding affinity
P. aeruginosa PAO periplasmic extracts revealed similar levels of
periplasmic SPM-1 variants, with the exception of S84P and S84K
mutants, which were undetectable. We analyzed the thermal
stability of the mutants in periplasma, by studying the temperature
dependence of (1) periplasmic b-lactamase activity or (2) SPM-1
solubility for each mutant. Hydrolysis rates were evaluated at 30uC
after incubation at different temperatures. Instead, protein
solubility was analyzed by Western blot quantitation of the levels
of soluble SPM-1 variants after incubation at different tempera-
tures. A plot correlating the hydrolytic activities (or solubilities)
with the incubation temperature revealed in all cases a well-
behaved sigmoidal behavior, that can be fit to obtain apparent Tm
(Tmapp) values for each variant (Figure S1 and Table 1). Tmapp
values determined from both strategies display an astonishingly
good correlation.
The four most stable periplasmic SPM-1 variants were
G121S.S84/G121 (WT)<S84G/G121S$S84G, while the com-
bination S84D/G121S (naturally found in IMP-1) was the least
stable mutant together with G121D and, to a lesser extent,
G121A. At this point we selected some representative mutants for
further characterization (S84D, S84G, G121A, G121S, G121D,
G121N, S84D/G121S and wild type).
Host-Specific Enzyme-Substrate Interactions
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Figure 5. b-lactamase activity of SPM-1 mutants in P. aeruginosa periplasmic extracts against cephalotin (CFL), cephalexin (CFX),
ceftazidime (CAZ), cefepime (CFP) and imipenem (IMI). Rates of hydrolysis are normalized to the amount of periplasmic protein amounts
(Materials and Methods). Reactions were accomplished in Tris 10 mM, MgCl2 30 mM pH 7.3 and 800 mM antibiotic. Error bars come from activity
measurements from five independent periplasmic fractionations.
doi:10.1371/journal.ppat.1003817.g005
Host-Specific Enzyme-Substrate Interactions
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Similar experiments were performed with the apo-derivatives of
periplasmic SPM-1 variants, which were obtained by dialyzing the
periplasmic fractions against EDTA and DPA metal-chelators,
excess NaCl and finally metal-free reaction buffer. Tmapp values of
the apo variants were estimated as before by b-lactam activity (in
this case supplementing reaction media with 2 mM Zn(II)) and
protein solubility (Table 1).
Apo-derivatives exhibited a narrower range of Tmapp values,
suggesting that the main differences observed in the stability of
holo-derivatives are due to stabilization upon metal binding.
Mutant G121S showed the largest metal-induced stabilization
(,30uC difference in Tmapp between holo and apo derivatives).
Mutant S84D/G121S, on the other extreme, was marginally
stabilized by metal binding. Mutants G121A and G121D pre-
cipitated during Zn(II) removal. Mutants showing larger differ-
ences in stabilities between the apo and holo form are expected to
be those displaying large Zn(II) binding affinities. In agreement
with this hypothesis, the variants exhibiting the highest metal-
induced stabilization (wild type SPM-1, S84G, G121S and S84G/
G121S) were the least sensitive to metal deprivation (Figure 7).
We explored the structural effects of these mutations by
molecular dynamics (MD) simulations in wild type SPM-1 and
three selected variants: G121A, G121S and S84D/G121S [19].
After 5 ns of MD simulations, a water molecule from the bulk
solvent penetrates the active site of holo-wild type SPM-1, occu-
pying the vacant position between T115 and S84 (Figure S2), and
reconstructing the hydrogen bond network present in all B1
enzymes [19]. In the apo forms, Zn1 ligands become mobile,
mostly due to alterations in second sphere residues. The largest
changes were observed in the cavity between residues T115 and
S84. In WT SPM-1, the second sphere adopted two different
conformations: (a) ‘‘holo-like’’, in which the cavity was able to
accommodate water molecules connecting residues T115 and S84,
and (b) ‘‘apo-like’’, in which water molecules were excluded from
Figure 6. (A) Antibiograms of P. aeruginosa PAO pDEP-SPM-1 and P. aeruginosa 48-1997A against disks embedded with 30 mg
ceftazidime (CAZ), 30 mg cefepime (CFP) and 10 mg imipenem (IMI), alone or faced to 1.5 mg dipicolinic acid (DPA) containing disks.
Halos of inhibition are remarked with dotted lines. (B) Ceftazidime hydrolysis rates (300 mM) of crude extracts of P. aeruginosa PAO pDEP-SPM-1 and
P. aeruginosa 48-1997A, with and without 20 mM DPA. Reaction medium was 10 mM Tris, 30 mM MgCl2 at pH 7.3.
doi:10.1371/journal.ppat.1003817.g006
Figure 7. MIC values against cefepime of P. aeruginosa PAO containing SPM-1 mutants at different concentrations of the metal
chelator dipicolinic acid (DPA).
doi:10.1371/journal.ppat.1003817.g007
Host-Specific Enzyme-Substrate Interactions
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this network, and T115 and S84 show a direct interaction
(Figures 8 and S3). The holo and apo variants of G121S (the
mutant showing the highest metal-induced stabilization) closely
resemble the structure of the holo and apo forms of WT SPM-1.
Instead, in the case of the S84D/G121S, the second sphere re-
sidues are locked into an ‘‘apo-like’’ conformation, disfavoring
metal binding. In the case of G121A, the Ala121 side chain avoids
contraction of the cavity, locking the second sphere into the ‘‘holo-
like’’ form. The low stability of apo G121A suggests that this
conformation is not viable in the apo form.
Discussion
SPM-1 from P. aeruginosa is unique among pathogen-associated
MbLs in presenting the singular S84/G121 combination as second
sphere residues, instead of the conserved D84/R121 couple [13,19].
Here we report a thorough study of the impact of mutations in these
positions in the antibiotic resistance, specific enzymatic activity,
metal binding features and protein stability.
A major novelty in our approach is the extensive use of the
native host, P. aeruginosa. This approach allowed us: (1) to perform
a medium-throughput screening of activities and stabilities of a
series of mutants with a high degree of reproducibility, (2) to
correlate enzymatic activities reproducing the native conditions
(i.e., within the cell) during bacterial growth, which parallel the
resistance profile and (3) to identify additional environmental
factors which may not stem out from in vitro studies or by using
E.coli as a model bacterial host [9]. In fact, MIC values of
imipenem elicited by MbLs in E. coli are markedly lower to those
determined in their natural hosts [9,29]. In the particular case of
MbLs, these enzymes are active only when the Zn(II) availability
in the periplasm allows proper metal uptake, therefore being much
more dependent on the bacterial host than serine lactamases
[27,28].
Expression of WT SPM-1 in P. aeruginosa selectively raises the
MIC values against ceftazidime, cefepime and imipenem. These
MIC values correlate with the in periplasma specific activities,
in particular against cefepime and imipenem. The wild type
variant, together with G121A, shows the highest specific activities
against these two antibiotics. Instead, many single and double
mutants in positions 84 and 121 outperformed wild type SPM-1
versus several antibiotics to which P. aeruginosa is intrinsically
resistant. This remarkable substrate selectivity control by second
sphere residues shows that the atypical S84/G121 combination
present in SPM-1 has been fixed to provide resistance to anti-
pseudomonal drugs, while sacrificing the catalytic efficiency against
other antibiotics.
Analysis of the resistance profile against cefepime by control-
ling the Zn(II) availability in the external medium reveals that
G121A (the only variant able to compete with wild type SPM-1 in
terms of specific activity) is extremely sensitive to metal depri-
vation. The fact that G121A is not a natural variant of SPM-1
despite the high resistance observed in metal-rich media suggests
that evolutionary pressure has been exerted to select MbL
variants capable of providing resistance in low Zn(II) environ-
ments. Native SPM-1, instead, is able to confer resistance under
conditions of Zn(II) deficiency. Indeed, during infection, the
immune system produces large amounts of calprotectin, a host-
defense protein that prevents bacterial colonization by chelating
Mn(II) and Zn(II) [20,21]. Thus, optimization of the zinc binding
capabilities is a crucial evolutionary trait for MbLs in their
natural environment. This finding, together with a recent report
highlighting the need of proper assembly of a dinuclear site in the
active site of MbLs in the periplasm [28], highlights the need to
address the periplasmic bacterial mechanism of Zn(II) homeo-
stasis and its role in antibiotic resistance, which have been largely
overlooked.
The role of second sphere residues in catalysis is an emerging
issue in enzymology [30]. A hydrogen bond network connecting
metal binding residues below the active site is meant to preserve
the electrostatics and modulate the active site features. Directed
evolution experiments on the B1 enzyme BcII enzyme revealed
that mutations responsible of enhancing the lactamase activity
were located in this hydrogen bond network [31,32]. As analyzed
in detail by Spencer [19] and Oelshlaeger [33,34] in structural,
modeling and mutagenesis studies, this network spans metal
ligands His116, Asp120 and Cys221, and the second sphere
residues 115, 84, 121, 69, 70 and 262. The D84/R121 com-
bination is the most commonly found in B1 enzymes [35].
Molecular dynamics simulations showed that water molecules can
enter into the second sphere hydrogen bond network in SPM-1.
These calculations also support how changes in the second sphere
can modulate the Zn(II) binding affinity, ultimately impacting in
the resistance profile in limiting metal environments.
Most acquired MbLs, such as enzymes from the IMP, VIM and
NDM families present many allelic variants, in contrast to SPM-1
[36]. This difference could be due to the fact that SPM-1, as we
demonstrate here, is optimized to meet specific Pseudomonas re-
quirements, in contrast to the other MbL genes, present in many
different genera of bacteria.
In a broader perspective, our approach allowed us to investigate
how resistance determinants adapt to specific host requirements,
linking fine details of the structural and biophysical features of the
enzymes with bacterial fitness. More studies using this approach
are required to account for the versatility and adaptability of
MbLs to overcome the challenge imposed by new antibiotics.
Table 1. Values of Tmapp for different SPM-1 mutants and
their apo derivatives, measured in periplasmic extracts of P.
aeruginosa PAO by b-lactam hydrolysis rates and protein
solubility.
Tmapp (6C)
SPM-1 variant Holo-derivative Apo-derivative
Activity Solubility Activity Solubility
S84D 57.461.8 62.362.0 46.062.8 49.962.8
S84G 69.761.7 68.561.9 53.162.1 50.262.2
S84/G121 (WT) 71.962.0 73.161.6 46.962.0 55.562.1
G121A 61.061.6 62.561.5 -* -*
G121S 77.161.0 78.161.5 44.262.1 48.062.3
G121D 55.062.7 53.262.0 -* -*
S84D/G121S 55.362.3 56.462.5 42.562.0 53.162.1
S84K 58.062.0 nd nd nd
S84P 60.463.0 nd nd nd
S84N 64.660.4 nd nd nd
G121N 63.561.7 nd nd nd
S84N/G121S 64.060.7 nd nd nd
S84G/G121S 71.360.6 nd nd nd
S84Q/G121S 65.061.9 nd nd nd
S84G/G121N 66.862.8 nd nd nd
ndNot determined.
*The apo derivatives of these mutants precipitated during metal removal.
doi:10.1371/journal.ppat.1003817.t001
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Materials and Methods
Ethics statement
Rabbits were housed and treated according to the policies of the
Canadian Council on Animal Care guidelines on: antibody pro-
duction (http://www.ccac.ca/Documents/Standards/Guidelines/
Antibody_production.pdf). All efforts were made to minimize
suffering and the procedures were approved by the Bioethics
Commission for the Management and Use of Laboratory Animals
inside the Science and Technical Committee of the University of
Rosario, under resolution number 490/2012 (PICT-2008-Nu0405).
Bacterial strains
Escherichia coli DH5a (Gibco- BRL, Gaithersburg, MD, U.S.A.)
was used for construction of pDEP-SPM-1 plasmid. Pseudomonas
aeruginosa 48-1997A, originally identified in Brazil, was provided by
M. Castanheira and M. Toleman [13], and used as the source of
blaSPM-1. Laboratory strain P. aeruginosa PAO was used for trans-
formation of mutant libraries, microbiological and biochemical
studies. All strains were grown aerobically at 37uC in lysogeny
broth (LB) medium supplemented with antibiotics when necessary.
Recombinant DNA methodology
Molecular biology procedures were done according to Sam-
brook et al. Transcriptional unit of blaSPM-1 was PCR-amplified
from a genomic preparation of P. aeruginosa 48-1997A using
primers SPM-1-fw and SPM-1-rv (Table 2), both containing a
BamHI restriction site, and subcloned into pBBR1-MCS5 plasmid
[22]. The product was digested with XhoI and SmaI enzymes
(Promega) to eliminate restriction sites EcoRI and PstI from the
MCS of the plasmid. Extremes were made blunt by treatment with
Klenow fragment (Promega) and then ligated with T4 DNA ligase
(Promega). Restriction sites EcoRI and PstI were introduced at the
each edge of SPM-1 coding sequence by mutagenesis using
primers EcoRI-fw, EcoRI-rv, PstI-fw and PstI-rv (Table 2). The
resultant plasmid, pDEP-SPM-1, was introduced into P. aeruginosa
PAO by electroporation as described [37].
All constructs and amplifications were verified by sequencing at
the University of Maine (Orono, USA).
Codon randomization and selection of resistant clones
Codons corresponding to positions 84 and 121 (BBL numbering
[35]) of SPM-1 were randomized individually by Overlap Exten-
sion PCR, as previously described [23,24]. Mutagenic primers
were designed so as to contain random trinucleotides at the desired
positions (S84X-fw, S84X-rv, G121X-fw y G121X-rv, Table 2),
using pDEP-SPM-1 as the template [23,24]. The products were
subcloned into pDEP-SPM-1 through EcoRI and PstI restriction
sites (thus avoiding unwanted mutations in promoter or terminator
during PCR reactions), and the ligation mixtures electroporated in
P. aeruginosa PAO. Electrocompentents from each mutant library
(S84X and G121X) were spread in LB-agar plaques containing
30 mg/ml gentamicin, then collected and stored at280uC. Library
Figure 8. Simplified scheme of the H-bridge interaction network present in the different variants of SPM-1 under study. Holo and
apo-like conformations are highlighted in blue and yellow, respectively.
doi:10.1371/journal.ppat.1003817.g008
Table 2. Primers used in this work.
1 SPM-1-fw AGCTGGATCCCGCGACAAGGCCCAACTCAC
2 SPM-1-rv AGCTGGATCCCACCACCGAGGGCTCTTCAC
3 EcoRI-fw CGGAGATCGGAATGAATTCACCTAAATCGAGAG
4 EcoRI-rv CTCTCGATTTAGGTGAATTCATTCCGATCTCCG
5 PstI-fw CTCACATCCCCAACCCTGCAGTTAACGCTTTCAAAC
6 PstI-rv AGTCAGTCCTCGAGGGTTGGGGATGTGAGACTAC
7 S84X-fw GACCGTTGTCATTGTCNNNTCGCCGTTTGAAAATCTG
8 S84X-rv GATTTTCAAACGGCGANNNGACAATGACAACGGTCCC
9 G121X-fw GCACTTTCATTTGGACNNNACGGGTGGAAATGAAATTTAC
10 G121X-rv TTCATTTCCACCCGTNNNGTCCAAATGAAAGTGC
doi:10.1371/journal.ppat.1003817.t002
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of double mutants S84X/G121X was constructed by submitting a
plasmid preparation from S84X library to codon randomization of
position 121, in the same way as before.
Selection of mutants capable of conferring some degree of
resistance towards b-lactam antibiotics was done as follows. LB-
agar plaques were inoculated with a bacterial culture (O.D. 0.1) of
each mutant library, and disks embedded with 10 mg imipenem,
30 mg ceftazidime, 1000 mg cefoxitin, or 10 mg piperacillin placed
on top of the agar. Mutant clones growing in the area of the
antibiotic gradients were picked and the sequence of blaSPM-1
further determined [23].
Microbiological assays
Production and/or resistance levels of SPM-1 in P. aeruginosa
PAO pDEP-SPM-1 or P. aeruginosa 48-1997A were assayed by
pairing disks embedded with 1.5 mg dipicolinic acid (DPA) with
disks containing 10 mg imipenem, 30 mg ceftazidime or 30 mg
cefepime, onto LB-agar plaques inoculated with the corresponding
bacterial culture (O.D. 0.1) [25,38]. Minimal inhibitory concen-
trations (MICs) were determined on plaque by the dilution method
[38].
Cellular fractionation and protein level determinations
P. aeruginosa PAO crude extracts were obtained through soni-
cation of cells washed in Tris 10 mM, MgCl2 30 mM pH 7.3
followed by centrifugation at 4uC. Periplasmic preparations of P.
aeruginosa PAO were obtained by shock with chloroform as
previously described [39]. Contamination of periplasmic extracts
with cytoplasmatic proteins was discarded by Western-blot with
antibodies against cytoplasmatic DnaK [27].
Levels of periplasmic wild type SPM-1 and mutants were
determined by Western-blot of periplasmic extracts with poly-
clonal antibodies against SPM-1 (obtained after inoculating a
rabbit with a mixture of recombinant SPM-1 and Freund’s
adjuvant) and immunoglobulin G-alkaline phosphatase conjugate.
Protein band intensities were quantified with the Gel-Pro Analyzer
4.0 software (Exon-Intron, Inc.) and normalized to a bacterial
periplasmic protein arbitrarily chosen.
b-lactamase activity
Initial rates of hydrolysis were measured in a JASCO V550
spectrophotometer at 30uC in 300 ml of reaction media containing
300 mM of substrate and 10 ml of P. aeruginosa PAO periplasmic or
crude extract in 10 mM Tris, 30 mM MgCl2 at pH 7.3. For
comparison, hydrolytic activities of periplasmic extracts were
made relative to the amount of SPM-1 or mutant present in the
extract, estimated by Western-blot anti-SPM-1 of the extracts
normalized as before.
In order to study the contribution of SPM-1 in whole b-lactam
activity, crude extracts (normalized in total protein concentration
by Bradford assay [40]) were incubated during 20 minutes at room
temperature with and without addition of 25 mM DPA, and initial
rates measured and compared.
Thermal denaturation of periplasmic extracts
Aliquots from each periplasmic extract of P. aeruginosa PAO
were incubated for 5 minutes at various temperatures in the range
30–90uC, and then placed on ice for (a) determining initial rates of
hydrolysis against ceftazidime, or (b) determining the levels of
soluble SPM-1 or mutants (as before by Western-blot anti-SPM-1
of normalized extracts) after centrifugation for 10 min at
10,000 rpm and 4uC. Activity curves or soluble protein fraction
as a function of temperature was adjusted to the sigmoid curve
f = y0+a/(1+exp(2(x2x0)/b)) in Sigma Plot 9.0 program, with x0
the apparent melting temperature.
Extraction of Zn(II) from periplasmic extracts
In order to generate apo-derivatives of periplasmic SPM-1 and
mutants, periplasmic fractions of P. aeruginosa PAO were dialyzed
in duplicate against 500 mM EDTA, 500 mM DPA, 50 mM Tris
pH 8, then 2M NaCl, 50 mM Tris at pH 8, and finally 10 mM
Tris, pH 7.3 30 mM MgCl2. The solutions were previously
treated with chelating ion exchange resin (Chelex 100, Sigma-
Aldrich) and dialysis times were of 6 hours.
Molecular dynamic simulations
All simulations were performed in AMBER [41] starting from
the crystal structure of SPM-1 determined with resolution of 1.9 A˚
(PDB code 2FHX) [19]. As crystallization of SPM-1 was achieved
with a vacant Zn2 site, the metal site structure of SPM-1 was
reconstructed by aligning it to the geometry of the Zn2 site of the
homologous enzyme B. cereus BcII (PDB code 1BC2) [42]. In this
way, a starting structure with a complete active site was obtained.
Each simulation was performed using monomeric wild type SPM-
1, or mutant proteins G121S, G121A, S84D/G121S modified in
silico. Furthermore, three crystallographic azide molecules were
replaced by water molecules (Wt1, Wt2 and Wt3) in the cavities
present at the base of SPM-1 active site.
The systems were immersed in a box of water molecules TIP3P
[43] and were simulated using periodic boundary conditions and
Ewald sums for treating long-range electrostatic interactions [44].
The SHAKE algorithm was applied to all hydrogen-containing
bonds [45]. This allowed us to use a time step of 2 fs for inte-
gration of Newton equations. Parm99 and TIP3P force fields
implemented in AMBER were used to describe the protein and
water, respectively [41]. The force field of the active site (Zn,-OH,
Asp, Cys and His) was taken from the literature [46]. The
temperature and pressure were controlled by the Berendsen
thermostat and barostat respectively, as implemented in AMBER
[41]. Cut-off values used for the van der Waals interactions were
10 A˚. The systems were first minimized to optimize possible
structural crashes and then slowly heated from 0 to 300 K under
constant volume conditions, using a time step of 0.1 fs. Finally, a
short simulation was conducted at a constant temperature of
300 K and under constant pressure of 1 bar, using a time step
of 0.1 fs, to allow the systems reach a suitable density. These
balanced structures were the starting points for the 10 ns of
molecular dynamics simulations.
Supporting Information
Figure S1 Thermal denaturation curves for wild type SPM-1,
G121A, G121D, G121N, S84D, S84G and S84N/G121S mutants
in periplasmic fractions. In red, curves obtained after treating
periplasmic extracts with metal chelators. Below, SPM-1 Western-
blots of the soluble fractions of the periplasmic extracts pre-
incubated at different temperatures.
(TIF)
Figure S2 10 ns MD simulations of di-Zn(II) SPM-1. The
cartoon indicates the labeling of the water molecules in the active
site. After 5 ns of simulation, Wt4937 diffuses from the bulk
solvent into the protein interior, reconstructing the conserved
hydrogen bond network among second sphere residues.
(TIF)
Figure S3 Structures of holo and apo derivatives of wild type
(WT), G121S, G121A and S84D/G121S SPM-1 after 10 ns of
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simulation. Metal-ligand bonds are shown in solid lines and
second-shell interactions in dashed lines. On the right, evolution of
H-O distances of possible H bridges between residues 115 and 84.
For simplicity, Zn2 and Zn2-ligands C221 and H263 are omitted
in most representations.
(TIF)
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